Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK/Theravance Press Forward With Once-Daily LABA After FDA Vote On Asthma Class

This article was originally published in The Pink Sheet Daily

Executive Summary

Firms await Phase IIb results for new inhaled corticosteroid to develop Phase III testing plan for potential successor to Advair.
Advertisement

Related Content

New Foradil Inhaler Falls Prey To Concerns About Single-Entity LABA Products
FDA Panels Favor Advair, Symbicort Over Single-Entity LABA Products For Asthma
FDA Panels Favor Advair, Symbicort Over Single-Entity LABA Products For Asthma
Schering/Novartis To Develop Once-Daily Inhalation Combination For Asthma, COPD

Topics

Advertisement
UsernamePublicRestriction

Register

PS067161

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel